Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L D Piro

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Cancer|December 1, 1993
The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignanciesA Saven, L D Piro
Hematology and Cell Therapy|December 1, 1996
2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disordersA Saven, L D Piro
Annals of Internal Medicine|May 1, 1994
2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignanciesA Saven, L D Piro
Cancer Treatment and Research|January 1, 1996
2-Chlorodeoxyadenosine treatment of lymphomaA Saven, L D Piro
Leukemia|November 1, 1992
Lymphocytic leukemias: new insights into biology and therapyK A Foon, L D Piro
The New England Journal of Medicine|March 18, 1993
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabineA Saven, R H Lemon, L D Piro
Annals of Internal Medicine|September 15, 1994
2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosisA Saven, K A Foon, L D Piro
Hematology/Oncology Clinics of North America|April 1, 1994
Purine metabolism of lymphocytes. Targets for chemotherapy drug developmentC J Carrera, A Saven, L D Piro
Leukemia & Lymphoma|January 1, 1994
The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemiaL D Piro, D J Ellison, A Saven
Leukemia & Lymphoma|March 14, 1998
2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemiaR Gollard, W E Miller, L D Piro, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Cancer|December 1, 1993
The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignanciesA Saven, L D Piro
Hematology and Cell Therapy|December 1, 1996
2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disordersA Saven, L D Piro
Annals of Internal Medicine|May 1, 1994
2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignanciesA Saven, L D Piro
Cancer Treatment and Research|January 1, 1996
2-Chlorodeoxyadenosine treatment of lymphomaA Saven, L D Piro
Leukemia|November 1, 1992
Lymphocytic leukemias: new insights into biology and therapyK A Foon, L D Piro
The New England Journal of Medicine|March 18, 1993
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabineA Saven, R H Lemon, L D Piro
Annals of Internal Medicine|September 15, 1994
2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosisA Saven, K A Foon, L D Piro
Hematology/Oncology Clinics of North America|April 1, 1994
Purine metabolism of lymphocytes. Targets for chemotherapy drug developmentC J Carrera, A Saven, L D Piro
Leukemia & Lymphoma|January 1, 1994
The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemiaL D Piro, D J Ellison, A Saven
Leukemia & Lymphoma|March 14, 1998
2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemiaR Gollard, W E Miller, L D Piro, et al.
Pageof 5